Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
Triple-negative breast cancers (TNBCs) are more likely to occur in younger patients and have a poor prognosis. They are highly heterogeneous tumors consisting of different molecular subtypes. The only common characteristic among them is the absence of targets for endocrine therapy and human epiderma...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1244781/full |
| _version_ | 1827763856620912640 |
|---|---|
| author | Filomena Marino Carvalho |
| author_facet | Filomena Marino Carvalho |
| author_sort | Filomena Marino Carvalho |
| collection | DOAJ |
| description | Triple-negative breast cancers (TNBCs) are more likely to occur in younger patients and have a poor prognosis. They are highly heterogeneous tumors consisting of different molecular subtypes. The only common characteristic among them is the absence of targets for endocrine therapy and human epidermal growth factor receptor 2 (HER2) blockade. In the past two decades, there has been an increased understanding of these tumors from a molecular perspective, leading to their stratification according to new therapeutic strategies. TNBC has ushered breast carcinomas into the era of immunotherapy. The higher frequency of germline BRCA mutations in these tumors enables targeting this repair defect by drugs like PARP inhibitors, resulting in synthetic lethality in neoplastic cells. Additionally, we have the identification of new molecules to which this generation of smart drugs, such as antibody-drug conjugates (ADCs), are directed. In this review, we will discuss the trajectory of this knowledge in a systematic manner, presenting the molecular bases, therapeutic possibilities, and biomarkers. |
| first_indexed | 2024-03-11T10:56:37Z |
| format | Article |
| id | doaj.art-cd6d2b6a98c44918bbf39484aa4d5a47 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T10:56:37Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-cd6d2b6a98c44918bbf39484aa4d5a472023-11-13T06:35:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-11-011310.3389/fonc.2023.12447811244781Triple-negative breast cancer: from none to multiple therapeutic targets in two decadesFilomena Marino CarvalhoTriple-negative breast cancers (TNBCs) are more likely to occur in younger patients and have a poor prognosis. They are highly heterogeneous tumors consisting of different molecular subtypes. The only common characteristic among them is the absence of targets for endocrine therapy and human epidermal growth factor receptor 2 (HER2) blockade. In the past two decades, there has been an increased understanding of these tumors from a molecular perspective, leading to their stratification according to new therapeutic strategies. TNBC has ushered breast carcinomas into the era of immunotherapy. The higher frequency of germline BRCA mutations in these tumors enables targeting this repair defect by drugs like PARP inhibitors, resulting in synthetic lethality in neoplastic cells. Additionally, we have the identification of new molecules to which this generation of smart drugs, such as antibody-drug conjugates (ADCs), are directed. In this review, we will discuss the trajectory of this knowledge in a systematic manner, presenting the molecular bases, therapeutic possibilities, and biomarkers.https://www.frontiersin.org/articles/10.3389/fonc.2023.1244781/fullbreast cancerTNBCbiomarkersimmunotherapyPARP inhibitorsADCS |
| spellingShingle | Filomena Marino Carvalho Triple-negative breast cancer: from none to multiple therapeutic targets in two decades Frontiers in Oncology breast cancer TNBC biomarkers immunotherapy PARP inhibitors ADCS |
| title | Triple-negative breast cancer: from none to multiple therapeutic targets in two decades |
| title_full | Triple-negative breast cancer: from none to multiple therapeutic targets in two decades |
| title_fullStr | Triple-negative breast cancer: from none to multiple therapeutic targets in two decades |
| title_full_unstemmed | Triple-negative breast cancer: from none to multiple therapeutic targets in two decades |
| title_short | Triple-negative breast cancer: from none to multiple therapeutic targets in two decades |
| title_sort | triple negative breast cancer from none to multiple therapeutic targets in two decades |
| topic | breast cancer TNBC biomarkers immunotherapy PARP inhibitors ADCS |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1244781/full |
| work_keys_str_mv | AT filomenamarinocarvalho triplenegativebreastcancerfromnonetomultipletherapeutictargetsintwodecades |